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Abstract : There have been many reports on the overexpression of human epider-
mal growth factor receptor 2 （HER2） in patients with colon cancer.  However, the 
role and frequency of HER2 overexpression have not been clearly dened.  Anti-
HER2 therapy has been shown to improve the prognosis of HER2-positive patients 
with breast and stomach cancers.  In this study, we explored HER2 expression in 
patients with colon cancer at stages II and III by immunohistochemistry （IHC） 
and dual-color in situ hybridization （DISH）, and examined the correlation between 
HER2 expression and clinicopathological factors.  Moreover, we examined the cor-
relation between HER2 expression and mucin 1 （MUC1） expression.  The subjects 
were 121 patients with colon cancer at stages II and III who underwent surgery 
in our hospital during the period from 2007 to 2009.  Sections containing the 
deepest part of a lesion were subjected to immunostaining for HER2 and MUC1.  
HER2 expression was assessed in accordance with Ventana’s Guidelines for HER2 
Testing in Stomach Cancer, with sections comprising less than 10% of weakly to 
moderately stained tumor cells scored as 1 ＞ 2.  HER2 expression scored as 2 
was dened with sections comprising more than 10% of the weakly to moderately 
stained tumor cells.　Patients with a score of 1＞ 2 and 2 were also subjected to 
DISH using a Dual ISH HER2 kit.  MUC1 expression was scored according to 
the percentage of stained area as follows : 0, 0 to 5% ; 1, 5 to 50% ; and 2, 50% 
and higher.  Patients with a score of 1 and 2 were dened as MUC1-positive.  The 
analysis of HER2 by IHC yielded the following scores : 45 patients （37.2%）, 0 ; 
38 patients （31.4%）, 1 ; 14 patients （11.6%）; 1＞ 2 ; 24 patients （19.8%）, 2 ; and 0 
patients （0%）, 3.  For the 38 patients with a score of 1＞ 2 and 2, DISH returned 
ratios of HER2 to Chr17 expression （HER2 : Chr17 ratio） from 1.13 to 1.93 （mean 
= 1.46）.  There was no signicant correlation between HER2 expression and clini-
copathological factors.  The numbers of MUC1-positive patients according to HER2 
score were as follows : 22 patients （48.9%） in the score 0 group （45 patients）; 25 
patients （65.8%） in the score 1 group （38 patients）; 10 patients （71.4%） in the 
score 1＞ 2 group （14 patients）, and 22 patients （91.7%） in the score 2 group （24 
patients）.  There was a positive correlation between HER2 expression and MUC1 
expression.  Specically, MUC1 expression levels increased with HER2 expression 
level, and the percentage of MUC1-positive patients was significantly higher in 
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the HER2 score 2 group than in the HER2 score 0 group （P＜ 0.01）.  Rates of 
HER2 positivity by DISH or uorescence in situ hybridization （FISH） in patients 
who had an HER2 score of 2＋ by IHC were 45% and 24% in the patients with 
stomach and breast cancers, respectively.  However, the positivity rate was 0% in 
the patients with colon cancer in this study.  This result indicates that patients with 
colon cancer who have an IHC HER2 score of 2＋ are more likely to be HER2 
negative by DISH than patients with breast and stomach cancers, although larger 
cohort studies are required before a definitive conclusion can be made.  There 
was a positive correlation between HER2 expression and MUC1 expression in this 
study, although further examination is required because there were no patients who 
had an HER2 score of 3＋ or 2＋ by IHC and were HER2 positive by DISH in 
this study.  HER2 expression in colon cancer should be cautiously assessed by both 
IHC and DISH.
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Introduction
　The human epidermal growth factor receptor 2 （HER2） gene （also called HER2/neu, 
c-erbB-2） was identified as an oncogene that is similar in structure to the human epidermal 
growth factor receptor （EGFR） gene1）.  The HER2 gene encodes a transmembrane glycoprotein 
receptor that is activated by the phosphorylation of tyrosine residues and plays a role in cell 
proliferation via a p21/ras signaling pathway1）.
　Breast cancer patients with HER2 gene amplication or HER2 protein overexpression have 
a poor prognosis2，3）, and anti-HER2 therapy is currently indicated for breast, stomach, and gas-
troesophageal junction cancers 4-6）.  Although there have been many reports on the frequency of 
HER2 overexpression in colon cancer 7，8）, the role of this oncogene in such cancers is not clearly 
dened.
　In this study, we examined HER2 expression in patients with stage II and III colon cancer 
by immunohistochemistry （IHC） and dual color in situ hybridization （DISH）.  By a colorectal 
cancer treatment guideline（2010）, a postoperative adjuvant chemotherapy is recommended for 
stage III, and when stage II has the high possibility of a recurrence, a postoperative adjuvant 
chemotherapy is considered.  We also examined the correlation between HER2 expression and 
clinicopathological factors in these patients.
　It has also been reported that mucin 1 （MUC1） is highly expressed in severely atypical ade-
nomas and cancers of the colon, whereas it is scarcely expressed in the normal colon epithelium 
and mildly atypical adenomas 9）.  MUC1 expression is related to the extent and metastasis of 
cancers10）, and indeed, combination therapy with a MUC1 inhibitor has been reported to reduce 
trastuzumab （herceptin） resistance in breast cancer cells11）.  Based on this, we nally examined 
the correlation between MUC1 expression and HER2 expression in our study patients with 
colon cancer.
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Materials and Methods
Subjects
　The subjects were 121 patients with stages II and III primary colon cancer who underwent 
intestinal resection and lymph node dissection in our hospital during the period from 2007 to 
2009.  Of these, 71 patients （58.7%） were male and 50 patients （41.3%） were female, with a 
mean age of 68.8 years （range : 36～ 94）.  Of the 121 patients, 76 patients were diagnosed with 
stage II cancer, 44 patients with stage III, and one patient underwent intestinal resection only with 
Table 1　Circumferential rate is transverse diameter of the intestine ÷maximum transverse diameter of the tumor
There was no signicant correlation between HER2 expression and clinicopathological factors, and HER2 
expression seemed less useful as a predictive factor of prognosis.
Table 1-①  HER2 expression by Tumor characteristic
HER2 0（45）  HER2 1（38） HER2 1＞ 2（14） HER2 2（24）
Mean age 68.7（39～ 94） 68.8（40～ 88） 67.3（36～ 83） 69.8（40～ 87）
Gender Male 28   （62.2％） 23   （60.5％）  7   （50％） 13   （54.2％）
Female 17   （37.8％） 15   （39.5％）  7   （50％） 11   （45.8％）
Macroscopic type type1  3   （ 6.7％）  0  2   （14.3％）  0
type2 29   （64.4％） 29   （76.3％） 10   （71.4％） 20   （83.3％）
type3 11   （26.7％）  9   （23.7％）  2   （14.3％）  4   （16.7％）
type4  1   （ 2.2％） 0 0 0
0 - IIa＋ IIc  1   （ 2.2％） 0 0 0
Histological type tub1 15   （33.3％） 13   （34.2％） 5   （35.7％） 7   （29.2％）
tub2 24   （53.3％） 25   （65.8％） 9   （64.3％） 14   （58.3％）
muc  1   （ 4.4％） 0 0 1   （4.2％）
pap  1   （ 2.2％） 0 0 1   （4.2％）
por  4   （ 8.9％） 0 0 1   （4.2％）
Circumferential rate 74.6％（13～ 100） 72％（30～ 100） 63％（21～ 100） 67.8％（21～ 100）
Maximum diameter 
of tumor
54.1 mm（10～ 100）53.3 mm（20～ 90） 47.9 mm（15～ 80） 52.4 mm（17～ 90）
Table 1-②  HER2 expression by Tumor characteristic
HER2 0（45） HER2 1（38） HER2 1＞ 2（14） HER2 2（24）
ly 0 12（26.7％） 13（34.2％）  4（28.6％）  7（29.2％）
1 19（42.2％） 19（50％）  8（57.1％） 13（54.2％）
2 10（22.2％）  6（15.8％）  2（14.3％）  4（16.7％）
3  4（ 8.9％） 0　　　 0　　　 0　　　
v 0  6（13.3％）  7（18.4％） 1（7.1％）  5（20.8％）
1 23（19％） 20（52.6％）  8（57.1％） 10（41.7％）
2 15（33％） 10（26.3％）  3（21.4％）  9（37.5％）
3  1（ 2.2％） 1（2.6％）  2（14.3％） 0
N 0 25（55.6％） 25（65.8％）  8（57.1％） 18（75％）
1 14（31.1％） 10（26.3％）  5（35.7％）  5（20.8％）
2  4（ 8.9％） 3（7.9％） 1（7.1％） 1（4.2％）
3  1（ 2.2％） 0 0 0
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no need for lymph node dissection.  Table 1 summarizes the patient background characteristics.
Immunostaining
　For each patient sample, we selected the tissue section representing the deepest part of the 
lesion for HER2 and MUC1 immunostaining （Fig. 1, 2）.  HER2 expression was assessed in 
accordance with the Guidelines for HER2 Testing in Stomach Cancer12）.  The sections contain-
ing less than 10% of weakly to moderately stained tumor cells were scored 1＞ 2 in this study. 
Patients with a score of 1＞ 2 and 2 were also subjected to DISH using Ventana’s Dual ISH 
HER2 kit.
　MUC1 expression was scored according to the percentage of stained area as follows : 0, 0 to 
5% ; 1, 5 to 50% ; and 2, 50% and higher, with MUC1 positivity dened by a score of 1 and 2 13）.
Results
　The IHC analysis of HER2 expression produced the following scores : 45 patients （37.2%） had 
Fig. 1.  Immunohistochemical staining for HER-2/neu 
（H & E, ×100）.
Score 0 :  The sections containing less than 10% of 
weakly stained tumor cells
Score 1 : The sections containing more than 10% of 
weakly stained tumor cells
Score 2 : The sections containing more than 10% of 
weakly to moderately stained tumor cells
Fig. 2.  Immunohistochemical staining for MUC1 （H 
& E, ×100）.
MUC1 expression was scored according to the 
percentage of stained area as follows : 0, 0 to 
5% ; 1, 5 to 50% ; and 2, 50% and higher.  
The patients with a score of 1 and 2 were 
defined as being MUC1-positive.
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a score of 0 ; 38 patients （31.4%）, 1 ; 14 patients （11.6%）, 1＞ 2 ; 24 patients （19.8%）, 2 ; and 0 
patients （0%）, 3.  We considered 38 patients （31.4%） including those with a score of 1＞ 2 or 2 
as borderline positive for HER2 expression, while the 83 patients （68.6%） with a score of 0 or 
1 were considered HER2 negative.
　The 38 patients with a score of 1 ＞ 2 or 2 were subjected to DISH.  The ratios of the 
expression level of HER2 to that of Chr17 （HER2 : Chr17 ratio） ranged from 1.13 to 1.93, with 
an average value of 1.46.  In the cases of breast and stomach cancers, HER2 gene amplication 
is dened by a HER2 : Chr17 ratio of 2.2 or higher 12，14）.  According to this denition, none of 
the patients showed HER2 gene amplication in this study.
　Table 2 shows the clinicopathological factors of the patients classied into HER2 score groups. 
There was no signicant correlation between HER2 expression and patient age or gender ; the 
macroscopic type, histological type, circumferential rate, and maximum diameter of the tumor ; or 
the presence of lymphatic invasion, venous invasion, and lymph node metastasis.
　MUC1-positive patients were then classied into HER2 score groups as follows : 22 patients 
（48.9%） in the score 0 group （45 patients）; 25 patients （65.8%） in the score 1 group （38 
patients）; 10 patients （71.4%） in the score 1＞ 2 group （14 patients）; and 22 patients （91.7%） 
in the score 2 group （24 patients）.  There was a positive correlation between HER2 expression 
Table 2  Details of HER2 and MUC1 immunostaining
Clone Source of the primary antibody Dilution Antigen ritrieval Detction
HER2 4B5 VENTANA prediluted CC1 DAB
MUC1 Ma695 VENTANA 1:100 CC1 DAB
Fig. 3.  The percentage of MUC1-positive patients 
was significantly higher in the HER2 score 2 
group than in the HER2 score 0 group （P 
＜ 0.01）.  There was a positive correlation 
between HER2 expression and MUC1 
expression, whereby the MUC1 expression 
level increased with HER2 expression level.
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and MUC1 expression, indicating that MUC1 expression level increased with HER2 expression 
level, and the percentage of MUC1-positive patients was signicantly higher in the HER2 score 2 
group than in the HER2 score 0 group （P＜ 0.01）.
Discussion
　HER2 protein overexpression detected by IHC was reported in 15～ 25% of patients with 
breast cancer 2，3） and in 8～ 31% of patients with stomach cancer15）, while HER2 gene ampli-
cation and HER2 protein overexpression have been linked to a poor prognosis.  Moreover, 
a positive correlation was found between FISH results and IHC scores in patients with breast 
and stomach cancers, whereby the HER2 positivity rate by FISH increases with IHC score.  In 
patients with colon cancer, the levels of HER2 protein overexpression by IHC in previous 
reports range from 0 to 83%7，8，16-19）; however, studies published during the last ve years, from 
2008 onwards, report a HER2 protein expression level of approximately 10% 20，21）.
　In this study, no patient was found to be HER2 positive by both DISH and IHC.  Because 
the number of HER2-positive patients with colon cancer was smaller than those with breast and 
stomach cancers, we were unable to correlate the HER2 expressions by IHC and DISH in this 
study.  The results on HER2 expression in colon cancer show inconsistencies among the previous 
reports, and this could reect the varied mechanisms regulating HER2 gene expression.  More-
over, the interpretation of immunostaining results for colon cancer specimens may vary because 
there are no standardized criteria such as those prescribed for stomach and breast cancers 22，23）.
　There was no signicant difference in clinicopathological factors among the patients in each 
HER2 score group.  These ndings indicate that patients with colon cancer are more likely to 
express HER2 than those with breast or stomach cancers and that it is difcult to correlate 
HER2 expression with clinicopathological factors or to predict the clinicopathological prognosis 
on the basis of HER2 expression.
　HER2-positivity rates using FISH for patients with a borderline HER2 score of 2＋ by IHC 
have been reported to be approximately 24%24） and 45%4） in the patients with breast and 
stomach cancers, respectively.  Based on the present results, the patients with breast and stomach 
cancers who had a HER2 score of 2＋ by IHC should be re-examined by FISH.  In this study, 
none of the 24 patients with colon cancer who had an HER2 score of 2＋ by IHC were HER2 
positive by DISH, indicating that, unlike for patients with breast and stomach cancers, patients 
with colon cancer and with a HER2 score of 2＋ by IHC are likely to be HER2 negative by 
DISH.  Studies involving larger patient numbers are now required to validate this hypothesis.
　MUC1 is normally expressed on the luminal surface of many epithelial cells and also in some 
hematopoietic cells and activated T cells.  MUC1 is also called polymorphic epithelial mucin 
（PEM）, episialin, CD227 antigen, DF3 antigen, and epithelial membrane antigen （EMA）, and 
the expression of this protein has been related to cancer extent and metastatic potential10）.  In 
this study, 79 patients （65.3%） were MUC1-positive, which agreed with previous reports 9，10）, and 
the percentage of MUC1-positive patients was signicantly higher in the HER2 score 2 group 
than in the HER2 score 0 group （P＜ 0.01）.  Thus, there was a positive correlation between 
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HER2 expression and MUC1 expression.  This is a very interesting finding, although further 
examination of a larger number of patients is required in the future because there was no 
patient who had a HER2 score of 3＋ or 2＋ by IHC and was HER2 positive by DISH in this 
study.
　We examined HER2 expression in 121 patients with stage II or III colon cancer by IHC and 
DISH.  We found that HER2 expression in patients with colon cancer was weak and infrequent, 
and there was no signicant correlation between HER2 expression and clinicopathological fac-
tors.  Thus, HER2 expression seems less useful as a predictive factor of prognosis in such cancer 
patients.
　The patients with colon cancer in this study who had an HER2 score of 2＋ by IHC were 
likely to be HER2 negative by DISH, although the accumulation of more cases is required to 
draw denitive conclusions.  Nevertheless, the results suggest that HER2 expression should be 
assessed and determined carefully by both IHC and DISH.
　There was also a positive correlation between HER2 expression and MUC1 expression, 
although further examination will be required because there was no patient who had a HER2 
score of 3＋ or 2＋ in IHC and were HER2-positive in DISH in this study.
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